Palantir faces a $330 million test U.S. investors should watch closely

24 Sep 2026, 01:03 · The Fresno Bee

Palantir Technologies (PLTR) has a rapidly growing U.S. business. But a £330 million ($447 million) NHS contract in Britain is giving investors another issue to watch: what happens when the company’s expansion into foreign governments meets political resistance?

Lobbyists are urging Britain’s new government to review the contract awarded to Palantir to run the NHS Federated Data Platform. The agreement has a review point and an initial three-year commitment through February 2027.

But Palantir’s financial fortunes are unlikely to depend solely on the UK government’s decision. But for U.S. investors the spat provides a useful test of one of the company’s most important growth stories: whether Palantir can translate its government customer wins into a sustainable business overseas.

Palantir’s U.S. government business is booming

The U.K. scandal comes as Palantir’s U.S. government business is growing significantly.

In the second quarter, Palantir generated $809 million in U.S. government revenue, up 90% from a year earlier. U.S. commercial revenue was even larger at $764 million and increased 149%.

Overall revenue climbed 93% to $1.94 billion.

Palantir also booked $3.37 billion in overall contract value in the quarter, including a record $2.13 billion from U.S. commercial clients.

That is important because it puts the British debate into perspective.

The NHS contract is a big deal for Palantir’s foreign reach, but the company’s present growth engine is still strongly connected to the U.S.

For investors, it’s not just a matter of whether Britain preserves one contract. The question is whether opposition in Britain or elsewhere may make it difficult for Palantir to repeat its US government success elsewhere.

The $330 million NHS deal is approaching a key date

In 2023, the NHS awarded the Federated Data Platform contract to a consortium headed by Palantir. The deal, which may include up to 240 NHS organizations, could be worth up to £330 million over a maximum of seven years.

That first three-year commitment expires Feb. 15, 2027.

British authorities are studying the deal, and lawmakers and activists are urging the government to trigger the break provision.

Reuters reported in June that the administration was considering whether to prolong the arrangement or discontinue it at the end of its first term.

That’s a very clean timeframe investors can observe.

But a termination wouldn’t necessarily impact the U.S. growth trajectory for Palantir. But it may serve as a reference point for other governments thinking about whether to employ Palantir for sensitive public-sector data and processes.

MATT RAMEY / Getty Images

Britain shows the risk behind Palantir’s government strategy

Data, artificial intelligence, and what it calls sovereign capabilities are increasingly at the heart of Palantir’s offer to governments.

That technique has huge promise since governments operate big, complex systems that often need long-term software interactions.

But the same interactions might have unexpected hazards.

The NHS deal has been questioned on the basis of privacy, public trust, data sovereignty, and reliance on a U.S. IT company. A U.K. parliamentary committee has also advised the government to employ the break clause and to look at alternatives.

More Palantir:

Separately, five British police agencies recently opted not to renew a two-year Palantir experiment because of financial constraints and doubt about the project’s merits, the Financial Times said.

That does not mean a wider retreat for Palantir in Britain. But it does illustrate that government growth is not seamless.

The U.S. business gives investors some cushion

But there is an essential counterargument.

Palantir’s U.S. government revenue grew 90% in the latest quarter, while U.S. commercial revenue jumped 149%. The company also raised its full-year 2026 revenue outlook to roughly $8.15 billion.

So even if Palantir loses or does not extend the NHS deal, investors would have to measure that event against the considerably bigger U.S. growth prospect for the firm.

This makes the British contract a more compelling signal than a financial threat per se.

If governments overseas start to doubt Palantir’s position, investors may want to rethink expectations about how fast the business can translate its U.S. government success into worldwide expansion.

If Britain does go forward with the deal and Palantir continues to provide quantifiable advantages, the experience might instead bolster the company’s capacity to sustain substantial public-sector connections despite political scrutiny.

What U.S. investors should watch next

The immediate trigger is the U.K. government’s assessment of the NHS contract and the approach of the February 2027 break point.

But the greater concern is Palantir’s worldwide government pipeline.

The company’s rapid growth in the U.S. raises the question of whether it can replicate that model abroad, where procurement rules, political pressures, and data sovereignty concerns vary.

For PLTR investors the NHS fight is not only a tale about a £330 million contract.

It’s a test of just how lasting Palantir’s government growth can be beyond its home market.

The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.

This story was originally published September 23, 2026 at 6:03 PM.